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The CXCR4 Antagonist AMD3100 Has Dual Effects on
Survival and Proliferation of Myeloma Cells In Vitro
Introduction
Stromal cell-derived factor-1 (SDF-1) is a chemokine constitutively
expressed and produced in bone marrow stromal cells (BMSCs). It
induces the migration and homing of hematopoietic stem cells (HSCs)
and progenitor cells (HPCs) through signaling via the G protein-
coupled receptor CXCR4 (1). Myeloma cells also express CXCR4
(2) and respond to SDF-1, resulting in the trafficking and localization
of these cells in the bone marrow (BM) microenvironment (3). SDF-1
alone has minimal or negligible effects on the survival and growth
of myeloma cells in vitro (4), but many reports are consistent with
the SDF-1/CXCR4 axis being involved in the progression of
myeloma. For example, serum levels of SDF-1 are elevated in
patients with multiple myeloma (5), and CXCR4 expression
increases in extramedullary plasmacytoma, a manifestation of an
advanced stage of multiple myeloma (6). BM endothelial cells in
multiple myeloma secrete CXC chemokines, including SDF-1, that
mediate interactions with myeloma cells (7). Additionally, SDF-1
plays an important role in tumor neoangiogenesis, and blockade of
the SDF-1/CXCR4 axis attenuates tumor growth (8). These obser-
vations raise the possibility that modulation of the SDF-1/CXCR4 axis
could influence the biology of myeloma cells and the disease course.
AMD3100, a small bicyclam molecule, was originally developed
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Purpose
AMD3100, an antagonist of the CXCR4 chemokine receptor is soon to be used clinically for the
peripheral mobilization of hematopoietic stem cells (HSCs) in patients with multiple myeloma.
AMD3100 has been shown to activate a G protein coupled with CXCR4 and thus acts as a
partial CXCR4 agonist in vitro. Thus, we explored whether AMD3100 affected the survival and
proliferation of myeloma cells in vitro. 
Materials and Methods
The effects of AMD3100 on survival and proliferation of two myeloma cell lines (RPMI8226 and
U266) as well as CD138+ cells obtained from several patients with multiple myeloma were
analyzed by flow cytometry using annexin V and a colorimetric cell proliferation assay (CCK-8
assay). 
Results
AMD3100, but not T140, another CXCR4 antagonist, stimulated the proliferation of myeloma
cell lines and CD138+ primary human myeloma cells (-2-fold increase) in a dose-dependent
manner in serum-free culture for up to 5 days, which was inhibited by pretreating the cells
with pertussis toxin. AMD3100 enhanced the proliferation of U266 cells induced by
interleukin-6 and partially reversed AG490-mediated growth inhibition and apoptosis induced
by serum deprivation in RPMI8226 cells. AMD3100 induced the phosphorylation of Akt and
MAPK p44/p42 in U266 cells and MAPK p44/p42 in RPMI8226 cells. In contrast, AMD3100
markedly increased the cell apoptosis and reduced the number of RPMI8226 cells after 5 to 7
days of culture under serum-free conditions.
Conclusion
AMD3100 exerts dual effects, initially enhancing and subsequently inhibiting the survival and
proliferation of myeloma cells, signaling viaCXCR4 in vitro.  
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T cells. It inhibits the binding of SDF-1 to CXCR4 and induces
peripheral mobilization of HSCs and HPCs (9). AMD3100 also
enhances the mobilization of HSCs induced by granulocyte colony-
stimulating factor (10). AMD3100 induces the segregation of leukemic
cells (11) and myeloma cells (12) in the BM microenvironment,
which is expected to enhance the chemosensitivity of the cells.
Based on these observations, AMD3100 is about to be used clinically
(13) for the peripheral mobilization of HSCs in patients with lym-
phoma and multiple myeloma. However, AMD3100 has been de-
monstrated to activate a G protein coupled with CXCR4, and thus acts
as a partial CXCR4 agonist in vitro (14). Additionally, AMD3100 was
shown to exert dual effects in bleomycin-induced lung inflammation
in an animal model (15). Thus, it is necessary to address the question
of whether AMD3100 functions as a partial agonist for CXCR4 in
lymphoma or myeloma cells before it is widely used in a clinical
setting. In this study, we explored whether AMD3100 affected the
proliferation and survival of myeloma cells in vitro.
Materials and Methods
1 Cells and reagents 
BM samples were obtained, with informed consent, from patients
with multiple myeloma at the time of diagnosis. CD138+ cells were
purified from BM using the MACS system (Miltenyi Biotec, Auburn,
CA) according to the manufacturer’s protocol. The human myeloma
cell lines RPMI8226 and U266 were purchased from the American
Type Culture Collection (ATCC; Manassas, VA) and cultured in
RPMI-1640 medium (Gibco-BRL Life Technologies, Grand Island,
NY) supplemented with 10% fetal bovine serum (FBS; Gibco-BRL
Life Technologies). Hepatocellular carcinoma cell lines PLC/PRF5
and Hep3B were purchased from ATCC and cultured in RPMI-
1640 and Dulbecco’s modified Eagle medium (DMEM; Gibco-BRL
Life Technologies), respectively, supplemented with 10% FBS.
Interleukin-6 (IL-6) and SDF-1 were purchased from R&D Systems
(Minneapolis, MN). AMD3100 and pertussis toxin (PTX) were
acquired from Sigma Chemical Co. (St. Louis, MO). Another
CXCR4 antagonist T140 peptide (H-Arg-Arg-Nal-Cys-Try-Arg-
Lys-d Lys-Pro-Tyr-Arg-Cit-Cys-Arg-OH) was purchased from Pep-
tron Inc. (Daejeon, Korea). Signal-blocking agents which included
wortmanin, LY294002, AG490, PD98059, rapamycin and SB203580
were obtained from Calbiotech (Spring Valley, CA). 
2 Flow cytometry 
Cells were incubated with fluorescein isothiocyanate (FITC) or
phycoerythrin (PE)-conjugated monoclonal antibodies at 4℃ for 30
minutes and analyzed using a Coulter Elite flow cytometer (Coulter
Electronics Ltd., Hialeah, FL) or FACSCanto II flow cytometer (BD
PharMingen, San Diego, CA). The monoclonal antibodies used
were FITC- or PE-conjugated anti-CD138 (Mi15; BD PharMingen)
and PE-conjugated anti-CXCR4 (12G5; BD PharMingen). To
detect cytoplasmic CXCR4, the cells were permeabilized with a
saponin-based reagent (BD PharMingen) according to manufacturer’s
instructions and labeled. To detect apoptosis, cells were stained with
FITC-conjugated annexin V (BD PharMingen) according to the
manufacturer’s instructions and analyzed by flow cytometry.
3 Migration assay
For the transmigration experiments, cells (2×10
5 cells/well) were
loaded into the upper chamber of a 24-well Transwell plate con-
taining a 5-μ m microporous membrane (Corning-Costar, Cambridge,
MA) and were allowed to migrate into the lower chamber containing
100 g/mL SDF-1 for 4 hours. Migrated cells were counted, and the
fold-increase in the number of migrated cells compared to that in the
control (migration index) was calculated. 
4 Cell proliferation assay
The effects of SDF-1, IL-6, AMD3100, T140 and signal-blocking
agents on myeloma cell proliferation were measured using a colo-
rimetric assay kit (CCK-8 assay kit; Dojindo Laboratories, Tokyo,
Japan) based on the MTT assay, according to the manufacturer’s in-
structions. Briefly, 5×10
3 cells were incubated in 96-well plates in
serum-free X-VIVO medium (BioWhittaker, Walkersville, MA).
To detect the effect of AMD3100 on the proliferation of primary
CD138+ cells, IL-6 (20 ng/mL) was added to each well. After
incubation, 10 μ L of CCK-8 solution provided by the manufacturer
was added to each well. After 3h incubation at room temperature,
the optical density (OD) was measured using a spectrophotometer
(Molecular Devices Co., Sunnyvale, CA) and the fold-increase in
the OD compared to that of the control (proliferation index) was
calculated. 
5 Tumor cell colony assay 
Myeloma cells (8×10
3) were plated in triplicate in 35-mm tissue
culture dishes (Corning Costar), containing 1 mL of assay medium
consisting of X-VIVO medium (BioWhittaker) and 1.2% methyl-
cellulose (StemCell Technologies, Vancouver, Canada). After 3 to
15 days of incubation at 37℃ in 5% CO2 in air, the number of
colonies, defined as cell clusters consisting of more than five cells,
was scored under an inverted microscope.
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6 Western blot analysis 
Western blotting was used to detect the phosphorylation of
signaling molecules. Cells were starved in serum-free medium for
12 hours and then stimulated with cytokines or AMD3100. The cells
were collected by centrifugation, washed in phosphate-buffered
saline, and lysed by the addition of SDS sample buffer (187.5 mM
Tris-HCl [pH 6.8], 6% [w/v] SDS, 100% glycerol, 150 mM DTT,
and 0.03% [w/v] bromophenol blue). Equal amounts of protein from
each sample were separated by electrophoresis on 10% SDS-polya-
crylamide gels and transferred to polyvinylidene fluoride membranes
(Amersham Life Science, Arlington Heights, IL). The membranes
were blocked for 1 hour in Tris-buffered saline (TBS) containing
5% (w/v) milk and 0.1% Tween20, and then incubated with the
primary mouse or rabbit monoclonal antibody (Cell Signaling
Technology Inc., Danvers, MA) overnight at 4℃. The blots were
washed with TBS containing Tween20, incubated with anti-mouse
or anti-rabbit secondary antibody for 2 hours, and developed using
West-Zol Plus (iNtRON Biotechnology, Seoul, Korea). The
following antibodies were used: anti-phospho-Akt polyclonal
antibody (Ser473), anti-Akt polyclonal antibody, anti-phospho-
MAPK p44/p42 polyclonal antibody (Thr202, Tyr204), anti-MAPK
p44/42 polyclonal antibody, anti-phospho-Stat3 polyclonal antibody
(Tyr705), anti-Stat3 polyclonal antibody, anti-phospho-MAPK p38
polyclonal antibody (Thr180, Tyr182) and anti-MAPK p38
polyclonal antibody (all from Cell Signaling Technology).
7 Statistical analyses 
The results were expressed as the mean±standard deviation (SD)
of at least three experiments. Data were analyzed using Student’s t
test for paired samples. A p-value ＜0.05 was deemed to be statistically
significant.
Results
1 AMD3100 blocks the migration of myeloma cells in
response to SDF-1
Using flow cytometry, two myeloma cells and primary CD138+
cells were confirmed to express CXCR4 on the cell surface to
varying degrees (data not shown). In 4-hour transmigration assays
using the Transwell system, SDF-1 in the lower chamber induced
the transmigration of myeloma cells and primary BM CD138+ cells,
which was abolished by treating the cells in the upper chamber with
AMD3100 and T140 (Fig. 1A). Pretreating the cells in the upper
chamber with PTX (200 ng/mL) for 2 hours also markedly inhibited
the chemotaxis of the cells in response to SDF-1 (data not shown).
To further clarify the function of AMD3100 and T140, we
examined whether these agents induced the internalization of cell
surface CXCR4. Treating U266 cells with 10
-5 M AMD3100 or 10
-6 M
T140 for 3 hours in serum-free X-VIVO medium resulted in the
internalization of almost all surface CXCR4 (Fig. 1B).
2 AMD3100, but not T140, stimulates the proliferation
of myeloma cells in short-term incubation
To examine whether SDF-1 and AMD3100 affect the proliferation
of myeloma cells, the two myeloma cells and primary CD138+ cells
from three patients with multiple myeloma were incubated in serum-
free X-VIVO medium in the absence or presence of AMD3100 (10
-7
to 10
-5 M) or T140 (10
-7 M to 10
-5 M) for up to 3 days and analyzed
by a CCK-8 assay. SDF-1 alone did not affect the proliferation of
the myeloma cells (data not shown). AMD3100, but not T140, dose-
dependently increased the number of myeloma cells and the primary
CD138+ cells. After a 3-day incubation, 10
-5 M AMD3100 increased
the proliferation of RPMI8226 cells, U266 cells and primary
CD138+ cells by 1.8-, 1.4- and 1.3-fold, respectively, compared to the
control (all p＜0.05; Fig. 2A and 2B). These proliferation-enhancing
effects were more prominent in the presence of IL-6 in U266 cells,
but not in RPMI8226 cells (Fig. 2C). Pretreating the cells with PTX
for 2 hours abrogated the enhancement (Fig. 2D). AMD3100 did
not affect the proliferation of hepatocellular carcinoma PLC/PRF5
or Hep3B cells (data not shown), indicating that the proliferation-
enhancing effect of AMD3100 is not common to all cells.
3 AMD3100 inhibits serum deprivation-mediated apo-
ptosis of myeloma cells
To study whether AMD3100 has an effect on apoptosis in
myeloma cells, RPMI8226 cells were incubated in RPMI-1640
medium without FBS. After 24 hours, 15.2±2.7% of the cells were
annexin V-positive. AMD3100 slightly reduced this to 10.1±1.8%,
and it further decreased to less than 1% with the addition of IL-6
(Fig. 3A). The apoptosis-reducing effects of AMD3100 were
observed for up to 72 hours of incubation (Fig. 3B). Similar results
were obtained with U266 cells (data not shown). Dexamethasone
(10
-7 to 10
-5 M) minimally increased apoptosis in RPMI8226 cells;
this increase was unaffected by AMD3100 (Fig. 3). 
4 AMD3100 induces phosphorylation of signaling mo-
lecules in myeloma cells
We next examined whether AMD3100 induced the phospho-
rylation of Stat3, MAPK p38, Akt, and MAPK p44/p42, which are
involved in SDF-1-mediated signaling (16), using RPMI8226 and
U266 cells. Stat3, Akt and MAPK p44/p42 were all constitutively
phosphorylated in these cell lines, to varying degrees. In U266 cells,Cancer Res Treat. 2010;42(4):225-234
228 CANCER  RESEARCH AND  TREATMENT
10
-5 M AMD3100 alone enhanced the phosphorylation of Akt and
MAPK p44/p42 to a modest degree, but not that of Stat3 or p38
MAPK. SDF-1 induced the phosphorylation of MAPK p44/p42,
which was attenuated by AMD3100 (Fig. 4A). IL-6 enhanced the
phosphorylation of MAPK p44/p42, which was further enhanced by
AMD3100 (Fig. 4B). In RPMI8226 cells, AMD3100 alone slightly
enhanced the phosphorylation of MAPK p44/p42, but not the phos-
phorylation of Stat3 or Akt (Fig. 4C). We then examined other cell
types, including two hepatocellular carcinoma cell lines (PLC/PRF5
and Hep3B), to clarify whether the activation of the signaling
molecules induced by AMD3100 was specific to myeloma cells.
AMD3100 induced the phosphorylation of Akt in PLC/PRF5 and
Hep3B (Fig. 4D), indicating that AMD3100-induced activation of
these signaling molecules was not unique to myeloma cells.
5 Influence of signal-blocking agents on AMD3100-
induced proliferation of myeloma cells 
To further define the signaling pathway(s) involved in the
AMD3100-induced proliferation of myeloma cells, a proliferation
assay was performed in the presence of various signal-blocking agents.
First, RPMI8226 cells were incubated for 3 days with fixed concent-
rations of signal-blocking agents, which have been demonstrated to
significantly inhibit signaling molecules and are thus commonly
used in such experiments (10
-5 M AMD3100, 10 μ M LY294002, 100
nM wortmanin, 50 μ M PD98059, 10 μ M AG490, 50 nM rapamycin
and 10 μ M SB203580). The phosphatidyl inositol-3 (PI3) kinase
inhibitor wortmanin, MAPK p44/p42 inhibitor PD98059, the mTOR
inhibitor rapamycin, and the MAPK p38 inhibitor SB203580 did
not affect AMD3100-induced or spontaneous proliferation in these
cells. Another PI3 kinase inhibitor, LY294002, and a Jak2 inhibitor,
AG490, completely inhibited not only AMD3100-induced pro-
liferation, but also spontaneous proliferation of these cells (Fig. 5A).
Thus, the signal-blocking effects of these agents were unclear. 
To clarify the influences of these agents, we repeated the ex-
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periments using several lower concentrations of the agents. LY294002
at concentrations not inhibiting spontaneous proliferation (5 μ M or
less) also did not affect AMD3100-induced proliferation of the cells,
whilst AG490 dose-dependently inhibited spontaneous proliferation
and AMD3100-induced proliferation of the cells (Fig. 5B). Accordingly,
the signal-blocking effects were still unclear. However, these results
indicate that AMD3100 partially overcame the strong growth
inhibition in myeloma cells induced by AG490. 
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6 AMD3100 induces a marked inhibition of survival and
proliferation of myeloma cells during the late course
in extended period cultures
Because a recent report demonstrated that AMD3100 induces a
marked inhibition of survival in leukemic cells in culture for ex-
tended periods of up to 14 days (17), we further evaluated the effects
of AMD3100 on the proliferation of myeloma cells in cultures of
extended duration (up to 14 days). In controls, in which cells were
incubated in serum-free medium alone, the number of cells in-
creased for the first 5 days and then decreased. Again, AMD3100 at
a high concentration (10
-5 M) significantly enhanced proliferation of
RPMI8226 cells over the first 5 days of incubation. However, after 5
to 7 days of incubation, AMD3100 induced a marked decrease in the
number of cells compared to the control (Fig. 6A). Adding SDF-1 at
the beginning and at day 7 of the incubation did not affect the early
increase or subsequent decrease in the number of cells (Fig. 6B). To
confirm the biphasic dual effects of AMD3100 on survival and
growth of myeloma cells, we performed a tumor cell colony assay
using RPMI8226 cells. Consistent with the proliferation assay,
AMD3100 increased the number of colonies during the early period
of the assay, but it markedly decreased the number and size of the
colonies in later period of the assay (Fig. 6C and 6D). To define late
effects of AMD3100 on apoptosis of myeloma cells, RPMI8226
cells were incubated in RPMI-1640 medium without FBS for up to
14 days. AMD3100 diminished cell apoptosis to a modest degree
over the first 5 to 7 days, and then enhanced it compared with the
controls (Fig. 7).
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Fig. 6. AMD3100 induced a marked inhibition of survival in myeloma cells during the later course in extended-period cultures. (A) RPMI8226
cells were incubated with or without AMD3100 or T140 in serum-free medium for up to 14 days. Data are the mean±SD of the relative
proliferation index from three independent experiments. (B) RPMI8226 cells were incubated in the presence of stromal cell-derived factor-1
(SDF-1; 100 ng/mL), AMD3100 (10
-5 M) or combinations thereof in serum-free medium for up to 14 days. A representative result is shown. (C)
Effects of AMD3100 on the formation of tumor cell colonies were examined using RPMI8226 cells. Data are the mean±SD of the number of
RPMI8226 cell colonies from three independent experiments in which AMD3100 was added at 10
-5 M. (D) Representative profiles of the colony
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Discussion
AMD3100 is a well known specific antagonist of CXCR4, and
does not interact with other chemokine receptors (18). Several studies
have reported that AMD3100 blocks the binding of SDF-1 to
CXCR4, resulting in inhibition of migration or proliferation induced by
SDF-1 in many cell types (19,20). We report here for the first time
that AMD3100 at a high concentration, for example 10
-5 M (10 μ M),
stimulates the proliferation of myeloma cells in a short-term incu-
bation for up to 5 days and protects cells from serum deprivation-
induced apoptosis, which is puzzling given the well-known roles of
the SDF-1/CXCR4 axis and AMD3100 in multiple myeloma (5-7,21).
As myeloma cells produce and secrete SDF-1 (5), which may possibly
acts as an autocrine growth factor, we initially expected AMD3100
to inhibit proliferation of myeloma cells. Unexpectedly, 10
-5 M
AMD3100 clearly stimulated the proliferation of myeloma cells in a
short-term incubation for 3 days under serum-free conditions. The
migration-blocking and CXCR4-internalizing effects indicate that
AMD3100 is a specific antagonist of CXCR4. However, AMD3100
has also been demonstrated to activate a G protein coupled with
CXCR4 and thus acts as a partial CXCR4 agonist in vitro (14,22). In
the present study, we showed that AMD3100 alone induced the
phosphorylation of some signaling molecules in myeloma cells. The
proliferation-enhancing effects of AMD3100 in myeloma cells were
abrogated by pretreating the cells with PTX, a strong G protein-
coupled receptor antagonist. These results indicate that AMD3100
acts as a partial agonist for CXCR4 in myeloma cells. Phosphoryla-
tion of signaling molecules induced by AMD3100 was also observed
in other cell types. AMD3100 induced the phosphorylation of Akt in
two hepatocellular carcinoma cell lines, PLC/PRF5 and Hep3B,
which express cell surface CXCR4 to a limited degree. Thus, the
action of AMD3100 is not limited to myeloma cells.
We sought to define which signaling pathways were involved in
the AMD3100-mediated proliferation of myeloma cells. Wortmanin
and PD98059 did not affect the enhanced proliferation. In contrast,
both LY294002 and AG490 completely blocked the proliferation of
RPMI8226 cells at concentrations that are commonly used in signal-
blocking experiments (23,24). Thus, the signal-blocking effects of
these agents could not be explained; although AMD3100 partially
overcame the inhibition of RPMI8226 cell proliferation induced by
AG-490 dose-dependently.  
A recent study showed that AMD3100 strongly impaired survival
and stimulated the differentiation of leukemic cells, such as HL60
and U937, where these cells were incubated with AMD3100 at a
concentration of 10
-5 M for 7 to 9 days (17). Although the cells in-
vestigated in that study were different from those in our experiments, the
results were apparently contradictory. Hence, we performed additional
experiments in an attempt to clarify the apparent differences. RPMI8226
cells were incubated with AMD3100 under serum-free conditions for
up to 14 days. We found that  10
-5 M AMD3100 clearly enhanced
proliferation of the cells during the early course of incubation. However,
after 5 to 7 days of culture, the number of cells treated with AMD3100
decreased more rapidly as compared to control. A similar pheno-
menon was observed in U937 leukemic cells (data not shown). Thus,
the results of the two studies did not actually differ. It seems that the
investigators in the previous study overlooked the proliferation-
enhancing effects of AMD3100 in leukemic cells in the early course
of the incubation. Taken together, we suggest that AMD3100 alone
induces signaling through CXCR4 and initially enhances prolife-
ration and survival of myeloma cells, and then the SDF-1/CXCR4
blockade by AMD3100 induces subsequent rapid cell death later.
Nevertheless the mechanism of AMD3100-induced cell death remains
to be identified. Given that myeloma cells are a major source of plasma
SDF-1 (5), a reasonable explanation could be that AMD3100 binding
to CXCR4 results in a blockade of the autocrine loop of SDF-1. In the
present study, we showed that PTX alone markedly inhibited the
proliferation of myeloma cells. This result suggests that constitutive
intrinsic signaling from G protein-coupled receptors, including CXCR4,
may be important in the survival and proliferation of myeloma cells.
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Fig. 7. AMD3100 exerts biphasic effects on apoptosis induced by serum deprivation in myeloma cells. RPMI8226 cells were incubated with or
without AMD3100 in RPMI-1640 medium for up to 14 days. At indicated time points, apoptosis of the cells were analyzed by flow cytometry
after staining with annexin V and propium iodide (PI). Representative results of three independent experiments showing consistent results are shown.Thus, additional explanation would be that AMD3100 binding to
CXCR4 inhibited the intrinsic signaling derived from CXCR4. 
Conclusion
AMD3100 has dual effects, initially enhancing and subsequently
inhibiting, on survival and proliferation of myeloma cells via CXCR4
in vitro. Although the proliferation enhancement was modest and
only apparent in the early period of incubation and when AMD3100
was added at a high concentration, we need to be cautious in the
clinical application of this drug in patients with multiple myeloma.
In contrast, the marked inhibition of survival in myeloma cells in the
later period suggests a new therapeutic potential for AMD3100 in
multiple myeloma. Further studies using in an in vivo experimental
model are warranted.
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